Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 68.00% is in line with its 5-year average of 67.07%, around the middle of its 5-year range (58.96%–72.61%).
0.01% below its 12-month average of 68.01%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-27): 68.97%.
GROSS MARGIN
68.00%
GROSS MARGIN AVG TTM
68.01%
GROSS MARGIN AVG 3Y
66.98%
GROSS MARGIN AVG 5Y
67.07%
GROSS MARGIN AVG 10Y
68.51%
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-0.01%
CURRENT VS 3Y AVG
+1.52%
CURRENT VS 5Y AVG
+1.39%
CURRENT VS 10Y AVG
-0.75%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
42.76%
median of 562 covered companies
CURRENT VS SECTOR MEDIAN
+59.03%
vs the sector median at left
Market Cap
$918.96M
Gross Margin
65.08%
TTM Avg
65.58%
3Y Avg
65.74%
5Y Avg
65.17%
Market Cap
$882.01M
Gross Margin
99.98%
TTM Avg
98.71%
3Y Avg
99.36%
5Y Avg
-14.89%
Market Cap
$868.65M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$928.20M
Gross Margin
94.73%
TTM Avg
99.96%
3Y Avg
49.98%
5Y Avg
33.32%
Market Cap
$938.73M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$847.33M
Gross Margin
92.94%
TTM Avg
91.25%
3Y Avg
45.63%
5Y Avg
30.42%
Market Cap
$853.77M
Gross Margin
58.31%
TTM Avg
55.25%
3Y Avg
65.77%
5Y Avg
65.77%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Bioventus Inc. (BVS) | $905.78M | 68.00% | 68.01% | 66.98% | 67.07% |
| HealthStream, Inc. (HSTM)vs › | $918.96M | 65.08% | 65.58% | 65.74% | 65.17% |
| Arbutus Biopharma Corp (ABUS)vs › | $882.01M | 99.98% | 98.71% | 99.36% | -14.89% |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $868.65M | 0.00% | 0.00% | 0.00% | 0.00% |
| Kura Oncology, Inc. (KURA)vs › | $928.20M | 94.73% | 99.96% | 49.98% | 33.32% |
| CeriBell, Inc. (CBLL)vs › | $935.25M | 88.90% | 87.31% | 85.47% | 85.47% |
| MoonLake Immunotherapeutics (MLTX)vs › | $938.73M | 0.00% | 0.00% | 0.00% | 0.00% |
| Monte Rosa Therapeutics, Inc. (GLUE)vs › | $847.33M | 92.94% | 91.25% | 45.63% | 30.42% |
| Beta Bionics, Inc. (BBNX)vs › | $853.77M | 58.31% | 55.25% | 65.77% | 65.77% |
| Jade Biosciences, Inc. (JBIO)vs › | $818.57M | 0.00% | 0.00% | 0.00% | 0.00% |
Gross Margin
68.0%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-27 | 68.97% |
| 2026-03-28 | 67.88% |
| 2025-12-31 | 68.07% |
| 2025-09-27 | 66.95% |
| 2025-06-28 | 68.16% |
| 2025-03-29 | 65.76% |
| 2024-12-31 | 66.82% |
| 2024-09-28 | 67.32% |
| 2024-06-29 | 68.54% |
| 2024-03-30 | 68.27% |
| 2023-12-31 | 63.73% |
| 2023-09-30 | 65.28% |
| 2023-07-01 | 65.02% |
| 2023-04-01 | 62.09% |
| 2022-12-31 | 58.96% |
| 2022-10-01 | 65.70% |
| 2022-07-02 | 68.88% |
| 2022-04-02 | 64.54% |
| 2021-12-31 | 67.30% |
| 2021-10-02 | 72.61% |
| 2021-07-03 | 69.49% |
| 2021-04-03 | 72.83% |
| 2020-12-31 | 74.52% |
| 2020-09-30 | 72.71% |
| 2020-06-30 | 69.55% |
| 2020-03-28 | 72.78% |
| 2019-12-06 | 75.27% |
| 2019-12-06 | 73.63% |
| 2019-06-29 | 71.86% |
| 2019-03-29 | 71.86% |
| 2016-03-31 | 70.59% |
| 2015-03-31 | 68.50% |
